Danish pharmaceutical giant Novo Nordisk has announced a significant restructuring plan that will cut 11 % of its global workforce. The company, known for its anti‑obesity treatments Ozempic and Wegovy, will eliminate 9,000 jobs worldwide, including 5,000 positions in Denmark. The cuts are expected to save roughly $1.3 billion and are part of a broader effort to simplify the organization, improve decision‑making, and reallocate resources toward growth opportunities in diabetes and obesity.
Novo Nordisk’s success in these areas had previously driven rapid expansion, with the workforce growing from 43,700 in 2020 to 78,400 today. However, the share price has been declining since last year as competition intensifies in the U.S. market, particularly from rival treatments developed by Eli Lilly. CEO Mike Doustdar emphasized that the company must adapt to evolving, more competitive and consumer‑driven obesity markets. The “transformation” plan aims to meet rising global demand while competing in a more dynamic environment.
Despite the challenges, investors responded positively: the share price rose more than 3 % after the announcement, indicating approval of the restructuring. The job cuts will also have a notable impact on the Danish economy; the loss of 5,000 domestic positions is equivalent to about two months of job growth, and Nykredit bank chief economist Palle Sorensen described the cuts as “significant.”
Limited production capacity has led to the temporary authorization of “compound” or copycat versions of Ozempic and Wegovy, further increasing competition. Novo Nordisk’s treatments, which use analogues of the hormone GLP‑1 to regulate blood glucose and appetite, remain central to its strategy. While the company faces hurdles, its commitment to meeting rising global demand and staying competitive in a dynamic market remains a key focus, and the restructuring plan is expected to shape its future growth and competitiveness in the pharmaceutical industry.
Comments are closed for this story.